Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-11-18
2009-12-01
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S077000
Reexamination Certificate
active
07625920
ABSTRACT:
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
REFERENCES:
patent: 4349558 (1982-09-01), Bell
patent: 4349559 (1982-09-01), Bell et al.
patent: 4412995 (1983-11-01), Bell et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6831093 (2004-12-01), Scanlan et al.
patent: 2003/0073703 (2003-04-01), Coghlan et al.
patent: 2003/0176478 (2003-09-01), Scanlan et al.
patent: 0 000 471 (1978-12-01), None
patent: WO 99/41256 (1999-08-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 03/061651 (2008-07-01), None
R. Hirschmann, et al., J. Am Chem. Soc., vol. 85, p. 120, 1963.
J.H. Fried, et al., J. Am Chem. Soc., vol. 85, p. 236, 1963.
R. Hirschmann, et al., J. Am Chem. Soc., vol. 86, p. 1520, 1964.
R. Hirschmann, et al., J. Med. Chem., vol. 7, p. 352, 1964.
Abstract of Papers of the American Chem. Soc., 2001, 221, No. 260, Shah, N.; Scanlan, T.
Bioorganic & Medicinal Chemistry Letters, vol. 14, p. 5199-5203, 2004.
A. Ali, et al., Journal of Medicinal Chemistry, vol. 47, p. 2441, 2004.
R. Newton, Torax, vol. 55, p. 603,2000, “Molecular mechanisms of glucocorticoid acton: What is important?”.
Scanlan et al., STN International, HCAPLUS Database, Accession No. 2003:590999, Reg. Nos. 57102-89-6, 571202-90-9, 57120291-0, 571202-93-2, 57120294-3, 571202-95-4, 57120296-5, 571202-97-6, 571202-98-7 and 571202-99-8 (2006).
Daniel Edelstein, et al, 2007, “The Latest Options and Future Agents for Treating Male Hypogonadism”, Expert Opinion Pharmacother. 8(17), pp. 2991-3008.
Robert J. Meissner, Mar. 2009, “The Discovery and Development of Selective Androgen Receptor Modulator MK-0773”, American Chemical Society National Meeting, Salt Lake City, Utah, Slide Presentation pp. 1-38.
H. Maia et al, 2009, “Testosterone Replacement Therapy in the Climacteric: Benefits beyond”, Gynecol Endocrinol, vol. 25(1) pp. 12-20.
Meissner Robert S.
Perkins James J.
Aulakh Charanjit S
Camara Valerie J.
Merck & Co. , Inc.
Panzer Curtis C.
LandOfFree
Fluorinated 4-azasteroid derivatives as androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated 4-azasteroid derivatives as androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated 4-azasteroid derivatives as androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124268